drugset
drugset / Trial / NCT04572854

Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN

NCT04572854 ↗

Phase 2 Completed 13 enrolled Apellis Pharmaceuticals, Inc.
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a Phase 2, multicenter, open-label, randomized, controlled study designed to evaluate the safety and efficacy of pegcetacoplan in patients who have post-transplant recurrence of C3G or IC-MPGN.

Timeline

Start
2021-09-07
Primary completion
2023-02-27
Completion
2026-01-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Pegcetacoplan Peptide 1080 mg Subcutaneous

Indications

C3 glomerulonephritis dense deposit disease immunoglobulin-mediated membranoproliferative glomerulonephritis membranoproliferative glomerulonephritis